Skip to main content
. 2009 Jan 28;9:38. doi: 10.1186/1471-2407-9-38

Figure 5.

Figure 5

The effect of mevalonate pathway substrate replacement with mevalonate (Mev) at low, medium and high concentrations (5, 200, and 1537 μM respectively), geranylgeraniol (GG, 10 μM) and farnesyl diphosphate (FPP, 23 μM) on zoledronic acid (ZA) and fluvastatin (Fluva) activity in a recurrent ovarian cancer.